Trevi Therapeutics to Host Conference Call and Webcast on March 10th to Share Topline Results from the Phase 2a RIVER Trial of Haduvio in Patients with Refractory Chronic Cough [Yahoo! Fin...
Trevi Therapeutics, Inc. (TRVI)
Company Research
Source: Yahoo! Finance
clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC), today announced a conference call and live webcast taking place tomorrow, Monday, March 10th, 2025 , at 8:30 a.m. ET , to share topline results from the Phase 2a RIVER trial of Haduvio in patients with refractory chronic cough. Trevi Therapeutics, Inc. www.trevitherapeutics.com (PRNewsfoto/Trevi Therapeutics, Inc.) Conference Call The Company will host a conference call and webcast to review the topline results. The live webcast, including audio and presentation slides, will be accessible at the time of the meeting and can be accessed here . To participate in the conference call by phone, please dial (877) 870 4263 (domestic) or (412) 317 0790 (international) and ask to join the Trevi Therapeutics call. No code is necessary for access. An archived rep
Show less
Read more
Impact Snapshot
Event Time:
TRVI
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
TRVI alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
TRVI alerts
High impacting Trevi Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
TRVI
News
- Trevi Therapeutics (NASDAQ:TRVI) was given a new $18.00 price target on by analysts at Stifel Nicolaus.MarketBeat
- Trevi Therapeutics Announces Appointment of David Hastings as Chief Financial OfficerPR Newswire
- Trevi Therapeutics (NASDAQ:TRVI) was upgraded by analysts at B. Riley to a "strong-buy" rating.MarketBeat
- Trevi Therapeutics (NASDAQ:TRVI) had its "outperform" rating reaffirmed by analysts at Leerink Partners.MarketBeat
- Trevi Therapeutics: Big Cough Data, Bigger Execution Risk [Seeking Alpha]Seeking Alpha
TRVI
Earnings
- 11/13/25 - Beat
TRVI
Sec Filings
- 12/5/25 - Form 8-K
- 12/3/25 - Form 4
- 11/14/25 - Form SCHEDULE
- TRVI's page on the SEC website